Mara Epstein to Monoclonal Gammopathy of Undetermined Significance
This is a "connection" page, showing publications Mara Epstein has written about Monoclonal Gammopathy of Undetermined Significance.
Connection Strength
4.477
-
Epstein MM, Zhou Y, Castaneda-Avila MA, Cohen HJ. Multimorbidity in patients with monoclonal gammopathy of undetermined significance. Int J Cancer. 2023 06 15; 152(12):2485-2492.
Score: 0.811
-
Casta?eda-Avila MA, Mazor KM, Lapane KL, Epstein MM. Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS). Cancer Causes Control. 2023 May; 34(5):449-457.
Score: 0.811
-
Casta?eda-Avila MA, Lapane KL, Person SD, Zhou Y, Gurwitz J, Mazor KM, Epstein MM. Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance. Hematol Oncol. 2022 Aug; 40(3):409-416.
Score: 0.761
-
Casta?eda-Avila MA, Lapane KL, Person SD, Jesdale BM, Zhou Y, Mazor KM, Epstein MM. Differences in Hospital, Emergency Room and Outpatient Visits Among Adults With and Without Monoclonal Gammopathy of Undetermined Significance. Cancer Control. 2022 Jan-Dec; 29:10732748221126936.
Score: 0.748
-
Castaneda-Avila MA, Ulbricht CM, Epstein MM. Risk factors for monoclonal gammopathy of undetermined significance: a systematic review. Ann Hematol. 2021 Apr; 100(4):855-863.
Score: 0.699
-
Epstein MM, Saphirak C, Zhou Y, LeBlanc C, Rosmarin AG, Ash A, Singh S, Fisher K, Birmann BM, Gurwitz JH. Identifying monoclonal gammopathy of undetermined significance in electronic health data. Pharmacoepidemiol Drug Saf. 2020 01; 29(1):69-76.
Score: 0.646